UroGen Pharma (URGN) News Today $10.27 -0.25 (-2.38%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Barclays PLC Increases Stake in UroGen Pharma Ltd. (NASDAQ:URGN)Barclays PLC grew its position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 409.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,778 shares of the company's stock after acquiring an additional 48January 16, 2025 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at D. Boral CapitalD. Boral Capital restated a "buy" rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Wednesday.January 15, 2025 | marketbeat.comUroGen Pharma Highlights RTGel® Platform and Growth PlansJanuary 14, 2025 | tipranks.comBarclays PLC Has $759,000 Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)Barclays PLC raised its position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 409.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 59,778 shares of the company's stock after purchasing an additional 48,040 shares during the period. Barclays PLC oJanuary 1, 2025 | marketbeat.comBreakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)December 31, 2024 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of "Buy" from BrokeragesShares of UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) have been assigned an average rating of "Buy" from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recoDecember 31, 2024 | marketbeat.comPoint72 Asset Management L.P. Trims Stake in UroGen Pharma Ltd. (NASDAQ:URGN)Point72 Asset Management L.P. cut its position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 38.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,506,646 shares of the company's stock after sellDecember 7, 2024 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Rating of "Buy" from BrokeragesUroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) has earned a consensus rating of "Buy" from the six analysts that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1December 6, 2024 | marketbeat.comD. Boral Capital Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN)D. Boral Capital reiterated a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Friday.December 6, 2024 | marketbeat.comLong-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®December 5, 2024 | businesswire.comUGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBCDecember 5, 2024 | businesswire.comRTW Investments LP Boosts Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN)RTW Investments LP increased its stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 6.5% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,787,347 shares of the company's stock after buying an additional 230,000 shareDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Has $4.41 Million Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)Parkman Healthcare Partners LLC lifted its position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 26.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 347,541 shares of the company's stock aDecember 4, 2024 | marketbeat.comVestal Point Capital LP Purchases New Position in UroGen Pharma Ltd. (NASDAQ:URGN)Vestal Point Capital LP acquired a new position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 400,000 shares of the company's sNovember 29, 2024 | marketbeat.comGreat Point Partners LLC Sells 2,147,473 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)Great Point Partners LLC lowered its stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 73.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 758,786 shares of the company's stockNovember 27, 2024 | marketbeat.comUroGen Pharma publishes long-term Jelmyto follow-up study resultsNovember 26, 2024 | markets.businessinsider.comUroGen Announces Positive Complete Response Data For Long-Term Jelmyto Follow-Up StudyNovember 26, 2024 | markets.businessinsider.comUroGen Pharma: Choice Based On Near-Term High-Value PDUFANovember 13, 2024 | seekingalpha.comUroGen Pharma FY2024 EPS Estimate Lifted by HC WainwrightUroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - Equities researchers at HC Wainwright increased their FY2024 EPS estimates for UroGen Pharma in a report issued on Thursday, November 7th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($3.01) per share for tNovember 11, 2024 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price TargetNovember 10, 2024 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comUroGen Pharma Reports Q3 Results and Drug ProgressNovember 8, 2024 | markets.businessinsider.comUroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...November 7, 2024 | finance.yahoo.comOptimistic Buy Rating for Urogen Pharma Driven by Strong Jelmyto Sales and Promising UGN-102 Approval ProspectsNovember 7, 2024 | markets.businessinsider.comUroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comUroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025November 6, 2024 | finance.yahoo.comUroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation ConferenceNovember 5, 2024 | finance.yahoo.comRice Hall James & Associates LLC Acquires 199,110 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)Rice Hall James & Associates LLC increased its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 273.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 271,897 shares of the company's stock afterNovember 2, 2024 | marketbeat.comUroGen Pharma (URGN) to Release Quarterly Earnings on WednesdayUroGen Pharma (NASDAQ:URGN) will be releasing earnings before the market opens on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comInvestors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five yearsOctober 20, 2024 | finance.yahoo.comTD Cowen Keeps Their Buy Rating on Urogen Pharma (URGN)October 16, 2024 | markets.businessinsider.comUrogen Pharma (URGN) Receives a Buy from OppenheimerOctober 16, 2024 | markets.businessinsider.comUroGen Announces FDA Acceptance of its New Drug Application for UGN-102October 16, 2024 | businesswire.comEF Hutton Initiates Coverage of UroGen Pharma (URGN) with Buy RecommendationOctober 16, 2024 | msn.comUroGen Pharma (NASDAQ:URGN) Receives "Outperform" Rating from OppenheimerOppenheimer reaffirmed an "outperform" rating and set a $40.00 target price on shares of UroGen Pharma in a research note on Wednesday.October 16, 2024 | marketbeat.comWesbanco Bank Inc. Purchases New Stake in UroGen Pharma Ltd. (NASDAQ:URGN)Wesbanco Bank Inc. acquired a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 74,400 shares of the company's stock, valued at approximately $945,October 16, 2024 | marketbeat.comUroGen Pharma's (URGN) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday.October 15, 2024 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Lifted to Strong-Buy at EF Hutton Acquisition Co. IEF Hutton Acquisition Co. I upgraded UroGen Pharma to a "strong-buy" rating in a report on Monday.October 15, 2024 | marketbeat.comBuy Rating for UroGen Pharma Amidst Key Executive Appointment and Promising Drug PipelineOctober 14, 2024 | markets.businessinsider.comUroGen Pharma Appoints Chris Degnan To Succeed Don Kim As CFOOctober 9, 2024 | markets.businessinsider.comUroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...October 9, 2024 | finance.yahoo.comMarshall Wace LLP Buys Shares of 42,841 UroGen Pharma Ltd. (NASDAQ:URGN)Marshall Wace LLP purchased a new stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 42,841 shares of the company's stock, valued at approximately $7October 9, 2024 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comUroGen Pharma (NASDAQ:URGN) Stock, Insider Trading ActivityOctober 5, 2024 | benzinga.comMillennium Management LLC Grows Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)Millennium Management LLC grew its stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 2,672.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,160,899 shares of the company'sOctober 5, 2024 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of UroGen Pharma in a research report on Thursday.October 3, 2024 | marketbeat.comPoint72 Asset Management L.P. Purchases 1,337,257 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)Point72 Asset Management L.P. raised its position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 120.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,449,277 shares of the company's stock after purchasing an addiSeptember 26, 2024 | marketbeat.comGreat Point Partners LLC Increases Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)Great Point Partners LLC raised its stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 10.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,906,259 shares of the company's stock after purchasing aSeptember 24, 2024 | marketbeat.comUroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy NowSeptember 23, 2024 | msn.comUroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR StockSeptember 23, 2024 | msn.com Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address URGN Media Mentions By Week URGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. URGN News Sentiment▼0.740.44▲Average Medical News Sentiment URGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. URGN Articles This Week▼42▲URGN Articles Average Week Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Zymeworks News Today Rocket Pharmaceuticals News Today Poseida Therapeutics News Today Bicycle Therapeutics News Today Oculis News Today CureVac News Today Cogent Biosciences News Today AbCellera Biologics News Today Phibro Animal Health News Today Nuvation Bio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:URGN) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
